Abstract: An example grip rejection method includes detecting a touch on a touch screen, where the touch covers an area of the touch screen. The grip rejection method includes in response to detecting a touch, determining touch coordinates representing the touch area with a touch controller. The grip rejection method includes in response to determining the touch coordinates with the touch controller, determining grip rejection information with the touch controller, where the grip rejection information includes signal strength information of the touch. The grip rejection method includes transmitting the touch coordinates and the grip rejection information of the touch.

Abstract: Disclosed is a test device and method for remote control parking, falling within the technical field of testing. The method provided by the present disclosure includes the following steps: responding to a remote control parking instruction sent by a portable terminal, and acquiring position and pose data of a vehicle in real-time; injecting function loss conditions; determining a stopping position of the vehicle according to the position and pose data if an alarm signal or a parking success signal sent by an in-vehicle infotainment system is received; and determining a test result of remote control parking according to the stopping position of the vehicle and the function loss conditions. The present disclosure is used to test the response of a vehicle parking under the function loss condition.

Abstract: A mechanical-hydraulic integrated releasing device includes an upper joint, a lower joint and a pawl. The upper joint and the lower joint are respectively connected to two ends of the pawl. An outer side of the pawl is sleeved with a releasing sleeve capable of moving in an axial direction of the pawl. A step is arranged on an outer wall of a ratchet of the pawl. A groove matching the step is arranged on an inner wall of the releasing sleeve, and the step and the groove cooperate to limit the pawl. A releasing sleeve upper portion is arranged between the releasing sleeve and the upper joint, one end of the releasing sleeve upper portion is inserted into the releasing sleeve, and the other end is sleeved on an outer portion of the upper joint and connected to the upper joint via a start pin.

Abstract: A vegetable oil-based cartilage bionic cushioning and shock-absorbing material, and a preparation method and use thereof, is provided. The vegetable oil-based cartilage bionic cushioning and shock-absorbing material is prepared from a premix A and an isocyanate mixture B; the premix A including a vegetable oil-based modified polyol, a type 1 polyether polyol, a type 2 polyether polyol, a polymer polyol, a surfactant, a foaming agent, a chain extender, a catalyst and a cell regulator; the type 1 polyether polyol is a polyether polyol with a molecular weight of 400-1000 and a hydroxyl value of 110-280 mgKOH/g; and the type 2 polyether polyol is a polyether polyol with a molecular weight of 1000-10000 and a hydroxyl value of 25-56 mg KOH/g. The material provided by the present invention is environment-friendly and breathable with open cells, and has a high cushioning effect and a low permanent compression set value.

Abstract: A mechanical-hydraulic integrated releasing device includes an upper joint, a lower joint and a pawl. The upper joint and the lower joint are respectively connected to two ends of the pawl. An outer side of the pawl is sleeved with a releasing sleeve capable of moving in an axial direction of the pawl. A step is arranged on an outer wall of a ratchet of the pawl. A groove matching the step is arranged on an inner wall of the releasing sleeve, and the step and the groove cooperate to limit the pawl. A releasing sleeve upper portion is arranged between the releasing sleeve and the upper joint, one end of the releasing sleeve upper portion is inserted into the releasing sleeve, and the other end is sleeved on an outer portion of the upper joint and connected to the upper joint via a start pin.

Abstract: A vegetable oil-based cartilage bionic cushioning and shock-absorbing material, and a preparation method and use thereof, is provided. The vegetable oil-based cartilage bionic cushioning and shock-absorbing material is prepared from a premix A and an isocyanate mixture B; the premix A including a vegetable oil-based modified polyol, a type 1 polyether polyol, a type 2 polyether polyol, a polymer polyol, a surfactant, a foaming agent, a chain extender, a catalyst and a cell regulator; the type 1 polyether polyol is a polyether polyol with a molecular weight of 400-1000 and a hydroxyl value of 110-280 mgKOH/g; and the type 2 polyether polyol is a polyether polyol with a molecular weight of 1000-10000 and a hydroxyl value of 25-56 mg KOH/g. The material provided by the present invention is environment-friendly and breathable with open cells, and has a high cushioning effect and a low permanent compression set value.

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.

Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.

Abstract: Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119.

Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119.

Abstract: The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.